Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2020  |  Volume : 16  |  Issue : 7  |  Page : 1691-1697

Efficacy and safety of transcatheter arterial chemoembolization combined with either 125I seed implantation or apatinib in hepatocellular carcinoma with portal vein tumor thrombosis: A retrospective comparative study

Minimally Invasive and Interventional Department, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China

Correspondence Address:
Hailiang Li
The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jcrt.JCRT_1587_20

Rights and Permissions

Aims: The aims of the study were to compare the efficacy and safety between transcatheter arterial chemoembolization (TACE) combined with 125I seed implantation (TACE-125I) or with apatinib (TACE-Apatinib) in HCC-portal vein tumor thrombosis (PVTT) patients. Setting and Design: We retrospectively evaluated the medical records of consecutive patients with HCC-PVTT who had undergone treatment with either TACE-125I or TACE-Apatinib between January 2018 and June 2019. Materials and Methods: The response was assessed at the last follow-up, and the outcomes were compared between the two groups. Progression-free survival (PFS), overall survival (OS), and treatment-related complications were evaluated. Statistical analysis used the 2-sample Student's t-test and Fisher's exact test. Results: This study enrolled 48 patients; 21 were treated with TACE-Apatinib and 27 with TACE-125I. For PVTT, the disease control rate (DCR) was 23.81% in the TACE-Apatinib group and 77.78% in the TACE-125I group. The objective response rate (ORR) in the TACE-Apatinib group was remarkably lower. The DCR of intrahepatic lesions was 85.71% in the TACE-Apatinib group and 81.48% in the TACE-125I group. There was no statistically significant difference in the ORR of intrahepatic lesions. Median OS was significantly longer in the TACE-125I group (13.3 vs. 10.8 months). Similarly, the median PFS was significantly longer in the TACE-125I group (9.7. vs. 6.6 months). Multivariate and univariate analyses showed that TACE-125I was an independent prognostic factor for OS. Conclusions: Compared with TACE-Apatinib, TACE-125I seed implantation can effectively prolong PVTT progression, PFS, and OS in HCC patients with PVTT.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded7    
    Comments [Add]    

Recommend this journal